Sanofi (NASDAQ:SNY) Now Covered by Analysts at The Goldman Sachs Group

Research analysts at The Goldman Sachs Group assumed coverage on shares of Sanofi (NASDAQ:SNY) in a research note issued to investors on Friday, Marketbeat reports. The brokerage set a “neutral” rating and a $65.00 price target on the stock. The Goldman Sachs Group’s price target indicates a potential upside of 14.24% from the company’s previous close.

Other research analysts also recently issued reports about the stock. Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “sell” rating to a “hold” rating in a research note on Thursday, January 30th. Finally, StockNews.com cut shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Three research analysts have rated the stock with a hold rating, one has issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Sanofi presently has an average rating of “Moderate Buy” and a consensus price target of $62.50.

Sanofi Stock Down 1.5 %

Shares of SNY opened at $56.90 on Friday. Sanofi has a one year low of $45.22 and a one year high of $60.12. The company has a market cap of $144.40 billion, a P/E ratio of 22.85, a P/E/G ratio of 1.01 and a beta of 0.58. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. The firm has a 50 day simple moving average of $54.55 and a two-hundred day simple moving average of $52.89.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings data on Thursday, January 30th. The company reported $0.70 EPS for the quarter, meeting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. Research analysts forecast that Sanofi will post 4.36 EPS for the current fiscal year.

Institutional Trading of Sanofi

Several institutional investors have recently modified their holdings of SNY. Victory Capital Management Inc. grew its stake in shares of Sanofi by 27.6% in the third quarter. Victory Capital Management Inc. now owns 8,669 shares of the company’s stock worth $500,000 after purchasing an additional 1,876 shares during the last quarter. Prospera Financial Services Inc grew its stake in shares of Sanofi by 5.6% in the third quarter. Prospera Financial Services Inc now owns 11,432 shares of the company’s stock worth $659,000 after purchasing an additional 604 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Sanofi in the third quarter worth $8,728,000. First Horizon Advisors Inc. grew its stake in shares of Sanofi by 15.6% in the third quarter. First Horizon Advisors Inc. now owns 7,375 shares of the company’s stock worth $425,000 after purchasing an additional 998 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA grew its stake in shares of Sanofi by 4.8% in the third quarter. Massachusetts Financial Services Co. MA now owns 147,955 shares of the company’s stock worth $8,527,000 after purchasing an additional 6,796 shares during the last quarter. Institutional investors own 14.04% of the company’s stock.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.